Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by bball67on Jan 10, 2025 8:40am
88 Views
Post# 36397492

RE:PMN faces delisting from NASDAQ (again)

RE:PMN faces delisting from NASDAQ (again)Based on the previous delisting notice last July? The market cap requirement was $35M. The shares outstanding today are a little short of 35M shares, so the required share price is approximately $1 per share. They only need to have the price at that level for a week. Re the current price, it is ridiculously low. There are 3 analysts that have price targets between $6.50 and $9+. I like the way Promis is distancing itself from the past by emphasizing they are not targeting plaque. I am very confident that PMN will be successful, 250k shares. The time to short this stock is over. Promis management is expected to be at the JPM Healtcare conference this weekend and early next week. 
<< Previous
Bullboard Posts
Next >>